Aptinyx (APTX) Misses Q2 EPS by 4c

Go back to Aptinyx (APTX) Misses Q2 EPS by 4c

Aptinyx Reports Second Quarter 2021 Financial Results and Business Highlights

August 10, 2021 4:10 PM EDT

Enrollment on track in both Phase 2b chronic pain studies with NYX-2925data readouts expected 1H 2022

Enrollment on track in Phase 2 cognitive impairment study with NYX-458data readout expected 2H 2022

Completed FDA meeting on NYX-783 developmentexpect to initiate Phase 2b studies in PTSD in 4Q 2021 and 1Q 2022

Initiating CEO transition planeffective January 1, 2022, Aptinyx CEO Norbert Riedel will assume role of executive chairperson and be succeeded by president and COO, Andy Kidd

Conference call today at 5:00 p.m. ET

... More